Ratings by Raymond James (Thomas Deal)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/8/2026 | Kymera Therapeutics | KYMR | New Coverage | Outperform (N/A) |
108.35 (106.33) |
-1.86% | Details | |
| 10/8/2026 | Odyssey Therapeutics | ODTX | New Coverage | Outperform (N/A) |
18.08 (16.73) |
-7.47% | Details | |
| 10/8/2026 | Palisade Bio Inc. | PALI | New Coverage | Outperform (N/A) |
1.48 (1.50) |
1.35% | Details | |
| 10/8/2026 | Nektar Therapeutics | NKTR | New Coverage | Market Perform (N/A) |
40.26 (36.83) |
-8.52% | Details |
